Trial Profile
A Phase II Study of Pembrolizumab (MK-3475) in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Diffuse large B cell lymphoma; Richter's syndrome
- Focus Therapeutic Use
- Acronyms KEYNOTE-170
- Sponsors Merck Sharp & Dohme
- 02 May 2023 Results of final analysis, published in the Blood
- 17 Jun 2022 Results from four KEYNOTE-013 (NCT01953692, n=20), KEYNOTE-087 (NCT02453594, n=31), KEYNOTE-170 (NCT02576990, n=5), and KEYNOTE-204 (NCT02684292) trials presented at the 27th Congress of the European Haematology Association
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition